Fifth ĀŅĀ׊ć Queen Square Motor Neuron Disease Centre Hybrid Symposium
06 September 2024, 9:30 amā6:00 pm
New Technologies, AI and Big Data for ALS: From genetics to physiology to therapies
This event is free.
Event Information
Open to
- All
Availability
- Yes
Cost
- Free
Organiser
-
Debbie Hadley – Department of Neuromuscular Diseases, ĀŅĀ׊ć Queen Square Institute of Neurology020 3108 2710
Location
-
Lecture Theatre378: Institute of Neurology, 33 Queen Square33 Queen SquareLondonWC1N 3BGUnited Kingdom
Programme
09:30 ā 09:40ĢżWelcome and an Introduction to the ĀŅĀ׊ć QS MND Centre:ĢżAndrea Malaspina, Clinical Academic Lead for MND, ĀŅĀ׊ć Queen Square
Session 1: Genetic Technologies
09:40 ā 10:00ĢżJan Veldink, University Medical Center Utrecht / UMC Utrecht Brain Center, Netherlands -ĢżProject MinE: the rare variant architecture of ALS in 2024
10:00 ā 10:20ĢżEran Hornstein, Department of Molecular Neuroscience, Weizmann Institute of Science, Israel -ĢżmiRNA in ALS
10:20 ā 10:40ĢżClotilde Lagier-Tourenne, Massachusetts General Hospital/Harvard Medical School -ĢżCombining genetic and pharmacological screens to identify new therapeutic targets in ALS
10:40 ā 11:00 Coffee Break
11:00 ā 11:20ĢżOscar Wilkins, ĀŅĀ׊ć Queen Square Institute of Neurology -ĢżNew Technologies for Gene Therapies in ALS
11:20 ā 11:40ĢżAndrew Bassett, Wellcome Sanger Institute -ĢżA CRISPR approach to studying neurodegenerative disease
Session 2: Proteins, Lipidomics and Metabolism
11:40 ā 12:00ĢżTammaryn Lashley, ĀŅĀ׊ć Queen Square Institute of Neurology -ĢżNew Pathologies in ALS and FTD
12:00 ā 12:20ĢżBenjamin Ryskeldi-Falcon, MRC Laboratory of Molecular Biology, University of Cambridge -ĢżAtomic pathology of ALS and FTD by cryo-EM of amyloid filaments
12:20 ā 12:40ĢżAdrian Isaacs, ĀŅĀ׊ć Queen Square Institute of Neurology -ĢżInsights from lipidomic approaches in ALS
12:40 ā 13:00ĢżLuc Dupuis, University of Strasbourg [Virtual] -ĢżFUS: a broad role in muscle and vulnerable neurons in neuromuscular diseases
13:00 ā 14:00 Lunch Break
Session 3: Immune System
14:00 ā 14:20ĢżSian Henson, William Harvey Research Institute ā Queen Mary University of London -ĢżImmune senescence and ALS
14:20 ā 14:40ĢżAlbert La Spada, University of California Irvine School of Medicine -ĢżDelineating Novel Pathways of Motor Neuron Demise in ALS
14:40 ā 15:10ĢżKEYNOTE:ĢżSteven Finkbeiner, Center for Systems and Therapeutics & Taube/Koret Center for Neurodegenerative Disease, Gladstone Institutes, University of California, San Francisco -ĢżAI and ALS: from image analysis to āthinkingā microscopy
15:10 ā 15:40 Tea Break
Session 4: AI and Big Data
15:40 ā 16:00ĢżJon Rohrer, ĀŅĀ׊ć Queen Square Institute of Neurology -ĢżDigital and remote biomarkers in ALS/FTD
16:00 ā 16:20ĢżOrla Hardiman, Trinity Biomedical Sciences Institute, Trinity College Dublin -ĢżPRECISION ALS
16:20 ā 16:40ĢżJames Cole, University College London, Department of Computer Science -ĢżMachine learning for multivariate prognostic models in MND
16:40 ā 16:50 10-minute comfort break
16:50 ā 17:10ĢżClive Svendsen, Cedars Sinai, Medical Center, California [Virtual] -ĢżUsing Answer ALS and organ chip models to revel specific deficits in iPSC derived motor neurons
17:10 ā 17:20ĢżBen Cryar, Principal Analyst Opportunity Assessment Group, LifeArc -ĢżLifeArcās Vision for Data & AI in ALS Research
17:20 ā 17:40ĢżBethan Kilpatrick, BenevolentAI -ĢżAI augmented target identification in ALS, taking a disease mechanism approach, exemplifiedĢżby our most advanced drug discovery programme
17:40 ā 17:50ĢżClosing RemarksĢżāĢżLinda Greensmith, Scientific Lead for NMD, ĀŅĀ׊ć Queen Square andĢżAmmar Al-Chalabi, Co-Director, UK MND Research Institute
Fifth ĀŅĀ׊ć Queen Square Motor Neuron Disease Centre International Symposium has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 6 category 1 (external) CPD credit(s)
Other events in this series